{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-003488","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2024-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.115476+00:00","generated_at":"2026-06-06T08:49:09.172921+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arrowhead reports Q1 revenue of $3.55M, down 94% YoY; operating loss $136.5M; cuts cash burn by up to $100M","bullets":["Revenue $3.55M vs $62.55M YoY; net loss $132.9M ($1.24 EPS) from $41.3M ($0.39 EPS) loss prior year.","Operating expenses $140.1M (R&D $116.5M, G&A $23.6M); operating loss $136.5M.","Cuts forward cash burn guidance by up to $100M (~$30M/qtr); completed $450M stock offering.","Terminated ARO-SOD1 and HZN-457; focuses on cardiometabolic, pulmonary programs; hired interim chief medical scientist."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-003488","json":"https://secwatch.observer/filing/0001628280-24-003488.json","markdown":"https://secwatch.observer/filing/0001628280-24-003488.md","text":"https://secwatch.observer/filing/0001628280-24-003488.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828024003488/0001628280-24-003488-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828024003488/arwr-20240206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T08:49:09.172921+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d6248e33bfb57892a79128ae0e49985780d63f58","claim":"ARROWHEAD PHARMACEUTICALS, INC. reported fiscal 2024 first quarter ended December 31, 2023 results: revenue $ 3,551, net income $ (132,864), EPS $ (1.24).","evidence_excerpt":"INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (in thousands, except per share amounts) Year Ended December 31, OPERATING SUMMARY 2023 2022 (Unaudited) Revenue $ 3,551 $ 62,546 Operating Expenses: Research and development 116,491 83,695 General and administrative expenses 23,605 20,985 Total Operating Expenses 140,096 104,680 Operating loss","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/879407/000162828024003488/0001628280-24-003488-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal 2024 first quarter ended December 31, 2023"},{"label":"Revenue","value":"$ 3,551"},{"label":"Net income","value":"$ (132,864)"},{"label":"EPS","value":"$ (1.24)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}